Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 18/20 | 0.45 |
| ▸ | WNT1 | P04628 | 8/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012523 | 1.00 | GSK3B (0.45) | GSK3BDYRK1AWNT1MMP2MMP13 | |
| SCHEMBL23033587 | 0.89 | GSK3B (0.43) | GSK3BDYRK1AWNT1MMP2MMP13 | |
| SCHEMBL23012913 | 0.77 | APP (0.46) | — | |
| SCHEMBL23033594 | 0.77 | ADRA2A (0.48) | — | |
| SCHEMBL23012217 | 0.74 | MAOB (0.57) | — | |
| SCHEMBL29479803 | 0.73 | MMP2 (0.51) | GSK3BDYRK1AWNT1MMP2MMP13 | |
| SCHEMBL23012957 | 0.73 | MMP2 (0.51) | GSK3BDYRK1AWNT1MMP2MMP13 | |
| SCHEMBL23033305 | 0.71 | HDAC6 (0.40) | GSK3BDYRK1AWNT1 | |
| SCHEMBL23012113 | 0.71 | MMP2 (0.51) | GSK3BDYRK1AWNT1MMP2MMP13 | |
| SCHEMBL29479678 | 0.71 | MMP2 (0.51) | GSK3BDYRK1AWNT1MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269725-B | Anti-influenza virus compound, preparation method and application thereof | 西藏海思科制药有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-114269725-A | Anti-influenza virus compound and preparation method and application thereof | 四川海思科制药有限公司 | 2022-04-01 | — | — | CN | disclosed |